I-mab

Mark Hagler, Chief Commercial Officer of NovaBridge Biosciences, received a significant stock option grant on July 8, 2026, as detailed in a Form 4 filing.

Lin Liwei Lorraine, General Counsel at NovaBridge Biosciences, received a significant employee stock option grant.

NovaBridge Biosciences CEO Srishti Gupta reports the acquisition of 3,000,000 employee stock options with an exercise price of $2.01.

Claire Xu Cong, SVP of Clinical Development at NovaBridge Biosciences, reported transactions involving ordinary shares and restricted stock units.

Director Fu Wei of NovaBridge Biosciences reported transactions involving employee stock options and restricted stock units.

Sean Wuxiong Cao, a Director and Chief Business Development Officer at NovaBridge Biosciences, reported significant equity transactions including the acquisition of Restricted Stock Units and Employee Stock Options.

An amendment to Schedule 13D reveals updated beneficial ownership percentages in NovaBridge Biosciences by Wei Fu and affiliated C-Bridge entities, with Mr. Fu holding 11.5%.

An amendment to Schedule 13D clarifies beneficial ownership of I-MAB shares by CBC Group entities and Wei Fu, explicitly disclaiming a 'group' with Everest Medicines Limited.

Everest Medicines Limited has acquired a significant stake in I-MAB, increasing its beneficial ownership to 16.1% through a recent underwritten offering.

A group of investment entities and individuals, led by Wei Fu, has significantly increased their beneficial ownership in I-MAB, triggering a Schedule 13D filing with the SEC.